CTOs on the Move

Century Therapeutics

www.centurytx.com

 
Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Greg Russotti
Chief Technology Officer and Interim Chief Executive Officer Profile

Funding

Century Therapeutics raised $160M on 03/03/2021

Similar Companies

Nitrome Biosciences

Nitrome Biosciences has discovered and identified a new class of enzymes.

DTx Pharma

DTx Pharma is a San Diego based startup with a novel technology for delivery of RNA medicines.

BlueSphere Bio

Rapid, Personalized T-cell Therapies for Cancer on BlueSphere Bio…

Cidara

Cidara is developing therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company`s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara`s proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California.

BioHarp UNI US

BioHarp UNI US is a Sun Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.